Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Betamethasone Valerate

&times

Overview

What is Betamethasone Valerate?

Betamethasone Valerate Cream, Ointment and Lotion contain betamethasone valerate USP, a synthetic adrenocortico-steroid for dermatologic use. Betamethasone, an analog of prednisolone, has a high degree of glucocorticoid activity and a slight degree of mineralocorticoid activity.

Betamethasone valerate is a white to practically white odorless crystalline powder practically insoluble in water, freely soluble in acetone and chloroform, soluble in alcohol, and slightly soluble in benzene and ether. Chemically, it is 9-fluoro-11β,17,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17-valerate. The structural formula is:

Each gram of the 0.1% Cream contains 1.2 mg betamethasone valerate (equivalent to 1 mg betamethasone) in a soft, white, hydrophilic cream of purified water, mineral oil, white petrolatum, polyethylene glycol 1000 monocetyl ether, cetostearyl alcohol, monobasic sodium phosphate and phosphoric acid or sodium hydroxide; chlorocresol is present as a preservative.

Each gram of the 0.1% Ointment contains 1.2 mg betamethasone valerate (equivalent to 1 mg betamethasone) in an ointment base of white petrolatum and mineral oil.

Each gram of the 0.1% Lotion contains 1.2 mg betamethasone valerate (equivalent to 1 mg betamethasone) in a vehicle of isopropyl alcohol and water slightly thickened with carbomer 934P. Phosphoric acid or sodium hydroxide is used to adjust pH.



What does Betamethasone Valerate look like?



What are the available doses of Betamethasone Valerate?

Sorry No records found.

What should I talk to my health care provider before I take Betamethasone Valerate?

Sorry No records found

How should I use Betamethasone Valerate?

Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of cortico-steroid-responsive dermatoses.

Apply a thin film of Betamethasone Valerate Cream or Ointment to the affected skin areas one to three times a day. Dosage once or twice a day is often effective.

Apply a few drops of Betamethasone Valerate Lotion to the affected area and massage lightly until it disappears. Apply twice daily, in the morning and at night. Dosage may be increased in stubborn cases. Following improvement, apply once daily. For the most effective and economical use, apply nozzle very close to affected area and gently squeeze bottle.


What interacts with Betamethasone Valerate?

Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.



What are the warnings of Betamethasone Valerate?

Sorry No Records found


What are the precautions of Betamethasone Valerate?

General:

Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.

Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.

Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.

Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (See ).

If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.

In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.











            Information for Patients:

            Laboratory tests:

            Carcinogenesis, Mutagenesis and Impairment of Fertility:

            Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.

            Pregnancy:

            Teratogenic Effects

            Pregnancy Category C.

            Nursing Mothers:

            not

            Pediatric Use: Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio.

            Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.

            Administration of topical corticosteroids to pediatric patients should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.


            What are the side effects of Betamethasone Valerate?

            The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria.


            What should I look out for while using Betamethasone Valerate?

            Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.


            What might happen if I take too much Betamethasone Valerate?

            Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (See ).


            How should I store and handle Betamethasone Valerate?

            Store at 25°C (77°F); excursions permitted to 15°C-30°C (59°F-86°F) [see USP Controlled Room Temperature].Store at controlled room temperature 15° - 30°C (59° - 86°F).E. FOUGERA & CO.A division of Nycomed US Inc.Melville, NY 11747I240D R12/07#57Relabeling of "Additional Barcode Label" by:Physicians Total Care, Inc.Store at controlled room temperature 15° - 30°C (59° - 86°F).E. FOUGERA & CO.A division of Nycomed US Inc.Melville, NY 11747I240D R12/07#57Relabeling of "Additional Barcode Label" by:Physicians Total Care, Inc.Store at controlled room temperature 15° - 30°C (59° - 86°F).E. FOUGERA & CO.A division of Nycomed US Inc.Melville, NY 11747I240D R12/07#57Relabeling of "Additional Barcode Label" by:Physicians Total Care, Inc.Store at controlled room temperature 15° - 30°C (59° - 86°F).E. FOUGERA & CO.A division of Nycomed US Inc.Melville, NY 11747I240D R12/07#57Relabeling of "Additional Barcode Label" by:Physicians Total Care, Inc.Store at controlled room temperature 15° - 30°C (59° - 86°F).E. FOUGERA & CO.A division of Nycomed US Inc.Melville, NY 11747I240D R12/07#57Relabeling of "Additional Barcode Label" by:Physicians Total Care, Inc.


            &times

            Clinical Information

            Chemical Structure

            No Image found
            Clinical Pharmacology

            Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions.

            The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.

            Non-Clinical Toxicology
            Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

            Indinavir is an inhibitor of the cytochrome P450 isoform CYP3A4. Coadministration of CRIXIVAN and drugs primarily metabolized by CYP3A4 may result in increased plasma concentrations of the other drug, which could increase or prolong its therapeutic and adverse effects (see and ).

            Indinavir is metabolized by CYP3A4. Drugs that induce CYP3A4 activity would be expected to increase the clearance of indinavir, resulting in lowered plasma concentrations of indinavir. Coadministration of CRIXIVAN and other drugs that inhibit CYP3A4 may decrease the clearance of indinavir and may result in increased plasma concentrations of indinavir.

            Array

            General:

            Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.

            Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.

            Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.

            Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (See ).

            If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.

            In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

            The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria.

            &times

            Reference

            This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
            "https://dailymed.nlm.nih.gov/dailymed/"

            While we update our database periodically, we cannot guarantee it is always updated to the latest version.

            &times

            Review

            Rate this treatment and share your opinion


            Helpful tips to write a good review:

            1. Only share your first hand experience as a consumer or a care giver.
            2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
            3. Fill in the optional information to help other users benefit from your review.

            Reason for Taking This Treatment

            (required)

            Click the stars to rate this treatment

            This medication has worked for me.




            This medication has been easy for me to use.




            Overall, I have been satisfied with my experience.




            Write a brief description of your experience with this treatment:

            2000 characters remaining

            Optional Information

            Help others benefit from your review by filling in the information below.
            I am a:
            Gender:
            &times

            Professional

            Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
            &times

            Tips

            Tips

            &times

            Interactions

            Interactions

            A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).